A Shocking Number Still Don't Know The Risk of Taking Aspirin Each Day
This comes from a survey of 1,771 people by the Annenberg Public Policy Center in Pennsylvania, on behalf of independent market research company SSRS. Respondents were quizzed on aspirin use and knowledge in November 2024.
In the past, aspirin's blood-thinning properties had led doctors to recommend a small daily dose of around 80 milligrams be taken by healthy, elderly patients to reduce their risk of heart attack or stroke.
That changed in 2019, when the American College of Cardiology and the American Heart Association (AHA) brought out new guidelines. The updated advice was that the risk of gastrointestinal bleeding from daily aspirin doses wasn't worth the reduced risk associated with cardiovascular disease and related issues.
"The most important way to prevent atherosclerotic vascular disease, heart failure, and atrial fibrillation is to promote a healthy lifestyle throughout life," state the guidelines.
"Aspirin should be used infrequently in the routine primary prevention of atherosclerotic cardiovascular disease because of lack of net benefit."
More than five years on, a number of people have yet to receive the message. As well as the 48 percent of respondents who still thought the effects of a daily dose of aspirin did more good than harm, another 39 percent weren't sure.
People in the youngest bracket (aged 18 to 39) were the most likely to know a daily aspirin is generally not recommended for most individuals. Those in the oldest bracket (aged over 60) were least likely to know – only 7 percent of this age group knew the drawbacks to aspirin outweigh the benefits, perhaps because for much of their lives, they've been told the opposite.
Studies have shown severe internal bleeding can be a consequence of repeatedly popping aspirin, interfering with process that protect the stomach's lining and potentially making inflammation and damage more likely.
However, the medical advice varies depending on your health history. For those who are known to be at an increased risk of heart problems, or those who have had a heart attack or stroke in the past, aspirin might be considered worth the risks in those cases.
The best advice you can follow is to consult your doctor before making any kind of change in your medication and ask them to check the latest guidelines on everything from aspirin to diet (which changes more often than you might think).
"Habits backed by conventional wisdom and the past advice of health care providers are hard to break," says Kathleen Hall Jamieson, director of the Annenberg Public Policy Center and this survey.
"Knowing whether taking a low-dose aspirin daily is advisable or not for you is vital health information."
There's Never Been a More Dangerous Time to Use Street Drugs. Here's Why.
New Strain of Bird Flu in Nevada Reveals a Concerning Mutation
Radical Study Proposes a Single Cause to Explain Alzheimer's Disease
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
6 days ago
- Yahoo
New study reveals single dietary factor that increases risk for heart disease: 'Our findings strengthen the importance'
New study reveals single dietary factor that increases risk for heart disease: 'Our findings strengthen the importance' An international study found that diets low in fiber may contribute to a higher risk of heart attacks, offering another reason to eat more plants. Researchers analyzed heart scans from nearly 1,400 people across Europe and Australia and discovered a clear link between low fiber intake and the buildup of dangerous plaques in the arteries. These plaques were more likely to rupture and lead to serious cardiac events. The study was published in the journal Cardiovascular Research and focused on people with existing coronary artery disease. "Our findings strengthen the importance of cardioprotective dietary recommendations," the researchers noted in the study's conclusion. The benefits of fiber were consistent even among those already taking heart medications or cholesterol-lowering drugs. While fiber has long been associated with improved digestion, reduced inflammation, and better blood sugar control, this study is among the first to directly connect fiber intake to the makeup of arterial plaques. Specifically, people who ate less fiber were more likely to have lipid-rich plaques, which are softer and more prone to rupture than fibrous or calcified plaques. That rupture risk can trigger heart attacks, even in people already on medication, making fiber an important yet often overlooked part of long-term heart care. A 2025 report from the American College of Cardiology linked plant-based eating patterns to a reduced risk of heart disease and stroke, indicating that other researchers have come to similar conclusions. And a long-term study from the Harvard T.H. Chan School of Public Health found that replacing red meat with legumes, nuts, or whole grains significantly lowered the risk of heart-related death, especially in younger adults. There are several health benefits. Fiber-rich diets are tied to reduced inflammation, improved cholesterol control, and more stable blood sugar, all of which can help prevent artery damage over time. Heart-healthy eating patterns such as the Mediterranean and DASH diets emphasize whole grains, vegetables, and legumes not only for weight control but also because they support long-term cardiovascular health. These findings align with other recent research that shows how dietary changes, even small ones, can lower the risk of chronic illness. Why do you eat plant-based foods? The health benefits It's cheaper It's good for the planet I prefer the taste Click your choice to see results and speak your mind. Join our free newsletter for easy tips to save more and waste less, and don't miss this cool list of easy ways to help yourself while helping the planet. Solve the daily Crossword
Medscape
08-07-2025
- Medscape
Vaccination Added to Pillars of Heart Disease Prevention
Evidence that major communicable diseases, including influenza, pneumococcus, and COVID-19, can lead to cardiovascular disease has prompted the European Society of Cardiology (ESC) to issue a consensus statement calling for routine vaccinations as a part of managing cardiovascular risk. Beyond preventing complications of the target infectious diseases, 'vaccinations have profound effects on the CV [cardiovascular] risk and as such should be considered the fourth pillar of medical CV prevention besides antihypertensives, lipid-lowering drugs, and medications that treat diabetes,' the statement read. The idea is not entirely new. In 2021, the society issued guidelines for heart failure that recommended flu and pneumococcal vaccinations to prevent hospitalizations from heart failure. In the 2023 guidelines on acute coronary syndromes from the American Heart Association (AHA) and American College of Cardiology (ACC), annual vaccination against flu was recommended for patients with a chronic coronary disease 'to reduce cardiovascular morbidity, cardiovascular death, and all-cause death.' The new statement differs by reviewing the 'extent to which infectious diseases can trigger CV morbidity and mortality,' an area with an expanding amount of data to provide evidence-based recommendations, according to Thomas F. Lüscher, MD, one of the corresponding authors of the document. In supporting vaccination as a major tenet of prevention, the statement provides 'more visibility and much more in-depth evidence than has been the case in the guidelines,' said Lüscher, who is the current president of the ESC and a consultant cardiologist at the hospital associated with King's College and the Imperial College in London, England. Due to a substantial increase in research regarding a variety of vaccinations, such as those for SARS-CoV-2 and respiratory syncytial virus (RSV), the statement is timely, Lüscher said. So far, on the basis of 'reasonably solid evidence,' vaccinations for influenza, SARS-CoV-2, and pneumococcus can all be recommended for reducing the risk for CV events. Citing several mechanisms by which infectious diseases contribute to CV risk, such as increased oxygen consumption by the myocardium and upregulation of inflammatory pathways, Lüscher and his coauthors predicted vaccinations for other infectious diseases are likely to join the list recommended for risk reduction when more evidence accrues. The ongoing registry-based randomized DAN-RSV trial now underway in Denmark aims to enroll 130,000 people and may provide evidence for RSV in particular, he and his colleagues stated. Vaccines applied for general public health must show a favorable benefit-to-risk ratio to gain regulatory approval. For patients with comorbidities, the relative protection from an acute disease might be even greater, but the consensus statement makes clear people with coronary artery disease receive an additional health benefit from at least some of these vaccines through reduced CV risk. Major complications from immunizations occur in fewer than 10 per 100,000 patients for approved vaccines and are generally controlled with prompt treatment, according to the ESC statement, citing multiple studies. Milder adverse events, such as injection site reactions or transient flu-like symptoms, are tolerable and, again, are outweighed by reducing the risk for CV events, the document stated. Myocarditis has been reported as a rare reaction to the SARS-CoV-2 vaccine, but this complication appears to occur mainly in younger men, typically resolves spontaneously, and is rarely severe. In addition, the authors of the consensus statement noted the risk for myocarditis from untreated COVID-19 has been estimated to be sixfold higher than myocarditis related to vaccination. According to the consensus statement, the strongest evidence for a CV benefit has been generated from trials with influenza and pneumococcal vaccines. In the multicenter double-blind IAMI trial, for example, which randomly assigned patients after an acute myocardial infarction to influenza vaccine or placebo, immunization was associated with a 41% reduction ( P < .014) in the risk for CV death over 12 months of follow-up. In a meta-analysis of studies evaluating the pneumococcal polysaccharide vaccine, protection was associated with a 10% reduction (95% CI, 0.84-0.99) for any CV event, including acute myocardial infarction, for patients aged 65 years or older. Observational data support a CV benefit from the SARS-CoV-2 vaccine, but the rationale is mostly supported by the evidence of protection from severe COVID-19 and long COVID, according to the consensus statement. No comparable document from the AHA/ACC has so directly addressed the role of vaccinations in reducing CV risk, but an AHA spokesperson, Suzanne Grant, vice president for Media Relations & Issues Management (National), pointed out that the 2025 AHA/ACC guidelines for the management of acute coronary syndromes gave annual influenza vaccination a level 1A recommendation for the specific goal of reducing the risk for major CV events. Other infectious diseases do not appear in those guidelines; however, the AHA spokesperson noted the evidence makes clear 'infections can trigger or worsen CV events in people with existing heart disease' and, so, supported the premise that vaccinations, at least for influenza, should be administered specifically for cardiac risk reduction. Lüscher noted the ESC consensus statement is not a new set of guidelines but rather an intensive review of evidence to guide clinicians in regard to this area of risk management. The timing is based mainly on the growing accrual of new evidence, but Lüscher acknowledged a second rationale for surveying the evidence. 'Another aspect is the conspiracy theories on vaccination,' he said. 'Here, we provide solid evidence that vaccination is more than just prevention or reducing the severity of infection but, indeed, has long-term benefits.'
Business Wire
07-07-2025
- Business Wire
Elucid Appoints Dr. Robert Pelberg as New Senior Vice President of Medical Affairs
BOSTON--(BUSINESS WIRE)-- Elucid, an AI medical technology company focused on providing physicians with a more precise view of atherosclerosis to drive patient-specific therapeutic decisions, has named Dr. Robert 'Bob' Pelberg as its new senior vice president of medical affairs. A highly accomplished cardiologist and nationally recognized expert in cardiovascular computed tomography angiography (CCTA), Dr. Pelberg brings to Elucid decades of clinical experience and a deep understanding of advanced imaging technologies and clinical research. In his new role, he will help shape and execute the company's clinical and research strategies and will lead the company's clinical operations quality efforts, ensuring compliance to the highest clinical quality and regulatory standards. 'Dr. Pelberg's appointment marks a critical step in Elucid's mission to deliver clinically valuable and scientifically rigorous tools to physicians." Share Dr. Pelberg's hiring comes at a pivotal moment for Elucid, as it accelerates both its clinical research strategy and commercial growth of its flagship product PlaqueIQ TM image analysis software. PlaqueIQ is the first and only FDA-cleared, non-invasive plaque analysis based on objective histology rather than subjective CCTA visual estimates. PlaqueIQ quantifies and classifies plaque morphology based on ground-truth histology, the gold standard for characterization of plaques. The software is designed to help physicians prioritize and personalize treatment based on actual disease, rather than population-based risk. 'Dr. Pelberg's appointment marks a critical step in Elucid's mission to deliver clinically valuable and scientifically rigorous tools to physicians. He will play a key role in expanding awareness of the company's software and key features within the medical community—engaging with clinicians, guiding study design, and articulating the clinical value of Elucid's histology-based technology in improving cardiovascular care, with our plaque analysis software today and our FFR-CT product in the near future,' said Kelly Huang, CEO of Elucid. 'Together, we are committed to helping align product development with real-world clinical needs, ultimately enhancing the impact of Elucid's work in transforming diagnostics for coronary artery disease.' Dr. Pelberg is board certified in cardiovascular diseases, cardiac CT angiography, nuclear cardiology and echocardiography. He is a fellow of the American College of Cardiology, the American Heart Association, the American Society of Echocardiography, the American Society of Nuclear Cardiology and the Society of Cardiovascular Computed Tomography. He is also the author and co-author of numerous books as well as clinical publications in the field of cardiac CT. With extensive leadership experience directing cardiovascular service line clinical operations, he most recently served as a clinical cardiologist and advanced cardiac imager at The Christ Hospital Heart and Vascular Institute. 'As physicians, we know the importance of having a clear understanding of each patient's coronary plaque and how that impacts their risk of future cardiac events, including heart attack and stroke, as well as how to care for each individual based on their own plaque assessment. I share Elucid's vision of a future where physicians will be able to incorporate patient specific plaque characteristics to create personalized care pathways in coronary artery disease that can ultimately help reverse the prevalence of heart attack and stroke,' said Dr. Pelberg. 'I look forward to contributing to the company's mission and helping deliver on that goal.' About Elucid Elucid is a Boston-based AI medical technology company dedicated to developing technology designed to provide physicians with a more precise view of atherosclerosis (coronary plaque buildup), the root cause of cardiovascular disease. The company's PlaqueIQ TM image analysis software is designed to help physicians prioritize and personalize treatment based on actual disease, rather than population-based risk of disease. PlaqueIQ includes the only FDA-cleared computed tomography angiography (CTA) algorithm that objectively quantifies plaque morphology validated against ground truth histology, the gold standard for characterization of plaque, as indicated by renowned pathologists. PlaqueIQ equips physicians with critical information regarding the type and amount of plaque in arteries that can lead to heart attack and stroke. Elucid is also pursuing an indication for FFR CT, derived from its plaque algorithm, to help identify coronary blockages and the extent of ischemia non-invasively. For more information, visit
